Prediction of excessive weight gain in insulin treated patients with type 2 diabetes
Authors:
- Simon Lebech CichoszSCSimon Lebech Cichosz
- Louise Lundby‐ChristensenLLLouise Lundby‐Christensen
- Mette D. JohansenMJMette D. Johansen
- Lise TarnowLTLise Tarnow
- Ole K. HejlesenOHOle K. Hejlesen
- The C.I.M.T. Trial GroupTGThe C.I.M.T. Trial Group
Open Access
- 30 April 2016
- journal article
- research article
- Published by Wiley in Journal of Diabetes
- Vol. 9 (4) , 325-331
Abstract
Background: Weight gain is an ongoing challenge when initiating insulin therapy in patients with type 2 diabetes mellitus (T2DM). However, if prediction of insulin‐associated weight gain was possible on an individual level, targeted initiatives could be implemented to reduce weight gain. The aim of the present study was to identify predictors of weight gain in insulin‐treated patients with T2DM.Methods: In all, 412 individuals with T2DM were, in addition to metformin or placebo, randomized into 18‐month treatment groups with three different insulin analog treatment regimens (biphasic, aspart, detemir). Participants with excessive weight gain were defined as the group with weight gain in the 4th quartile (>6.2 kg).We developed a pattern classification method to predict individuals prone to excessive weight gain.Results: Over the 18‐month treatment period, median weight gain among all 412 patients was 2.4 kg (95% prediction interval [PI] –5.6, 12.4 kg), whereas median weight gain for those in the upper 4th quartile (n = 103) was 8.9 kg (95% PI 6.3, 15.2 kg). No clinical baseline data were strong predictors of excessive weight gain. However, the weight gain during the first 3 months of the trial and the subsequent dose of insulin yielded a useful predictor for weight gain at the 18‐month follow‐up. Combining these two predictors into a prediction model with other clinical available information produced a receiver operating characteristic area under the curve of 0.80.Conclusions: We have developed a prediction model that could help identify a substantial proportion of individuals with T2DM prone to large weight gain during insulin therapy.Keywords
This publication has 27 references indexed in Scilit:
- Objective measurements of activity patterns in people with newly diagnosed Type 2 diabetes demonstrate a sedentary lifestyleDiabetic Medicine, 2013
- Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trialDiabetes, Obesity and Metabolism, 2012
- Effectiveness of Lifestyle Interventions for Individuals With Severe Obesity and Type 2 DiabetesDiabetes Care, 2011
- New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR)Journal of Internal Medicine, 2010
- Study rationale and design of the CIMT trial: The Copenhagen Insulin and Metformin Therapy TrialDiabetes, Obesity and Metabolism, 2009
- Insulin‐associated weight gain in diabetes – causes, effects and coping strategiesDiabetes, Obesity and Metabolism, 2006
- Insulin Treatment and the Problem of Weight Gain in Type 2 DiabetesThe Diabetes Educator, 2006
- Continuing metformin when starting insulin in patients with Type 2 diabetes: a double‐blind randomized placebo‐controlled trialDiabetic Medicine, 2005
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.Circulation, 1983